These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 19838127)

  • 1. Impact of tenofovir on renal function in HIV-infected, antiretroviral-naive patients.
    Horberg M; Tang B; Towner W; Silverberg M; Bersoff-Matcha S; Hurley L; Chang J; Blank J; Quesenberry C; Klein D
    J Acquir Immune Defic Syndr; 2010 Jan; 53(1):62-9. PubMed ID: 19838127
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tenofovir-induced renal toxicity in 324 HIV-infected, antiretroviral-naïve patients.
    Calza L; Trapani F; Tedeschi S; Piergentili B; Manfredi R; Colangeli V; Viale P
    Scand J Infect Dis; 2011 Aug; 43(8):656-60. PubMed ID: 21453205
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Renal function in patients with preexisting renal disease receiving tenofovir-containing highly active antiretroviral therapy in the HIV outpatient study.
    Young B; Buchacz K; Moorman A; Wood KC; Brooks JT;
    AIDS Patient Care STDS; 2009 Aug; 23(8):589-92. PubMed ID: 19591609
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Renal impairment in HIV-infected patients initiating tenofovir-containing antiretroviral therapy regimens in a Primary Healthcare Setting in South Africa.
    Kamkuemah M; Kaplan R; Bekker LG; Little F; Myer L
    Trop Med Int Health; 2015 Apr; 20(4):518-26. PubMed ID: 25442109
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of small body weight on tenofovir-associated renal dysfunction in HIV-infected patients: a retrospective cohort study of Japanese patients.
    Nishijima T; Komatsu H; Gatanaga H; Aoki T; Watanabe K; Kinai E; Honda H; Tanuma J; Yazaki H; Tsukada K; Honda M; Teruya K; Kikuchi Y; Oka S
    PLoS One; 2011; 6(7):e22661. PubMed ID: 21799928
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fanconi syndrome accompanied by renal function decline with tenofovir disoproxil fumarate: a prospective, case-control study of predictors and resolution in HIV-infected patients.
    Gupta SK; Anderson AM; Ebrahimi R; Fralich T; Graham H; Scharen-Guivel V; Flaherty JF; Fortin C; Kalayjian RC; Rachlis A; Wyatt CM
    PLoS One; 2014; 9(3):e92717. PubMed ID: 24651857
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Progressive renal tubular dysfunction associated with long-term use of tenofovir DF.
    Kinai E; Hanabusa H
    AIDS Res Hum Retroviruses; 2009 Apr; 25(4):387-94. PubMed ID: 19361280
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Renal safety of tenofovir in HIV-infected children: a prospective, 96-week longitudinal study.
    Viganò A; Zuccotti GV; Martelli L; Giacomet V; Cafarelli L; Borgonovo S; Beretta S; Rombolà G; Mora S
    Clin Drug Investig; 2007; 27(8):573-81. PubMed ID: 17638398
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized, pilot trial to evaluate glomerular filtration rate by creatinine or cystatin C in naive HIV-infected patients after tenofovir/emtricitabine in combination with atazanavir/ritonavir or efavirenz.
    Albini L; Cesana BM; Motta D; Focà E; Gotti D; Calabresi A; Izzo I; Bellagamba R; Fezza R; Narciso P; Sighinolfi L; Maggi P; Quiros-Roldan E; Manili L; Guaraldi G; Lapadula G; Torti C
    J Acquir Immune Defic Syndr; 2012 Jan; 59(1):18-30. PubMed ID: 21992924
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Kidney tubular abnormalities in the absence of impaired glomerular function in HIV patients treated with tenofovir.
    Labarga P; Barreiro P; Martin-Carbonero L; Rodriguez-Novoa S; Solera C; Medrano J; Rivas P; Albalater M; Blanco F; Moreno V; Vispo E; Soriano V
    AIDS; 2009 Mar; 23(6):689-96. PubMed ID: 19262355
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevalence and factors associated with renal dysfunction among HIV-infected patients.
    Crum-Cianflone N; Ganesan A; Teneza-Mora N; Riddle M; Medina S; Barahona I; Brodine S
    AIDS Patient Care STDS; 2010 Jun; 24(6):353-60. PubMed ID: 20515419
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of a tenofovir disoproxil fumarate plus ritonavir-boosted protease inhibitor-based regimen on renal function in HIV-infected individuals: a prospective, multicenter study.
    Cao Y; Han Y; Xie J; Cui Q; Zhang L; Li Y; Li Y; Song X; Zhu T; Li T
    BMC Infect Dis; 2013 Jul; 13():301. PubMed ID: 23815472
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term exposure to tenofovir continuously decrease renal function in HIV-1-infected patients with low body weight: results from 10 years of follow-up.
    Nishijima T; Kawasaki Y; Tanaka N; Mizushima D; Aoki T; Watanabe K; Kinai E; Honda H; Yazaki H; Tanuma J; Tsukada K; Teruya K; Kikuchi Y; Gatanaga H; Oka S
    AIDS; 2014 Aug; 28(13):1903-10. PubMed ID: 25259702
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk factors for chronic kidney disease in a large cohort of HIV-1 infected individuals initiating antiretroviral therapy in routine care.
    Kalayjian RC; Lau B; Mechekano RN; Crane HM; Rodriguez B; Salata RA; Krishnasami Z; Willig JH; Martin JN; Moore RD; Eron JJ; Kitahata MM
    AIDS; 2012 Sep; 26(15):1907-15. PubMed ID: 22824630
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Renal function declines more in tenofovir- than abacavir-based antiretroviral therapy in low-body weight treatment-naïve patients with HIV infection.
    Nishijima T; Gatanaga H; Komatsu H; Tsukada K; Shimbo T; Aoki T; Watanabe K; Kinai E; Honda H; Tanuma J; Yazaki H; Honda M; Teruya K; Kikuchi Y; Oka S
    PLoS One; 2012; 7(1):e29977. PubMed ID: 22242194
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of baseline renal function on tenofovir-containing antiretroviral therapy outcomes in Zambia.
    Mulenga L; Musonda P; Mwango A; Vinikoor MJ; Davies MA; Mweemba A; Calmy A; Stringer JS; Keiser O; Chi BH; Wandeler G;
    Clin Infect Dis; 2014 May; 58(10):1473-80. PubMed ID: 24585558
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incidence and risk factors for tenofovir-associated renal function decline among Thai HIV-infected patients with low-body weight.
    Chaisiri K; Bowonwatanuwong C; Kasettratat N; Kiertiburanakul S
    Curr HIV Res; 2010 Oct; 8(7):504-9. PubMed ID: 21073439
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Amprenavir and didanosine are associated with declining kidney function among patients receiving tenofovir.
    Crane HM; Kestenbaum B; Harrington RD; Kitahata MM
    AIDS; 2007 Jul; 21(11):1431-9. PubMed ID: 17589189
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Proximal renal tubular dysfunction related to antiretroviral therapy among HIV-infected patients in an HIV clinic in Mexico.
    Andrade-Fuentes K; Mata-Marín JA; López-De León JI; Manjarrez-Téllez B; Ramírez JL; Gaytan-Martínez J
    AIDS Patient Care STDS; 2015 Apr; 29(4):181-5. PubMed ID: 25101526
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Simplification of antiretroviral therapy to a single-tablet regimen consisting of efavirenz, emtricitabine, and tenofovir disoproxil fumarate versus unmodified antiretroviral therapy in virologically suppressed HIV-1-infected patients.
    Dejesus E; Young B; Morales-Ramirez JO; Sloan L; Ward DJ; Flaherty JF; Ebrahimi R; Maa JF; Reilly K; Ecker J; McColl D; Seekins D; Farajallah A;
    J Acquir Immune Defic Syndr; 2009 Jun; 51(2):163-74. PubMed ID: 19357529
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.